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Human epithelial ovarian cancer is the leading cause of death from
gynaecological malignancies among women in the Western world.
One out of 70 women develops the disease in the course of her life.
No effective screening methods are currently available. Most
women with ovarian cancer present with advanced disease at the
time of diagnosis. Current standard therapeutic options include
debulking surgery and adjuvant chemotherapy. 
The poor long-term outcome of ovarian cancer calls for novel
diagnostic as well as therapeutic strategies. One of these new ther-
apeutic approaches is corrective gene therapy aiming to inhibit
oncogene expression or to replace an inactivated tumour sup-
pressor gene by a wild-type copy. Current clinical experimental
gene therapy protocols (phase I and II) for ovarian cancer mostly
use recombinant retro- and adenoviruses as vehicles for gene
transfer (Barnes et al, 1997). 
A promising viral vector is the recombinant adeno-associated
virus (rAAV). This vector has characteristics that could be advan-
tageous when compared to other commonly used vector systems.
However, the potential of rAAV vectors in gene therapy for cancer
has not been widely explored yet. 
Wild-type (wt) AAV is not known to be pathogenic in humans
and does not replicate without a helper virus. An interesting
feature of the wild-type AAV is its tumour suppressive property
(Schlehofer, 1994). In addition, wtAAV-infected cancer cells seem
to be more sensitive to radio- and chemotherapy (Walz et al, 1992;
Hillenberg et al, 1999). Recombinant AAV vectors are derived
from the parental virus by deleting the rep and cap genes, which
can be replaced by a transgene and its regulatory sequences neces-
sary for expression. The only remaining sequences in cis in such
constructs are the ITRs (Samulski et al, 1989). rAAV vectors have
a broad host range including dividing as well as non-dividing cells,
low immunogenicity and lead to stable expression of the transgene
due to integration into the genome (Hallek and Wendtner, 1996). 
The classic rAAV production procedure involves co-transfection
of a plasmid containing a transgene flanked by the AAV ITRs and
a complementor plasmid supplying the rep- and  cap genes
(without ITRs) into HEK-293 cells, followed by infection with
adenovirus. Vectors are then concentrated and purified by 2 or 3
cycles of caesium chloride gradient ultra-centrifugation (Grimm
et al, 1998). In order to reach high numbers of recombinant infec-
tious particles, large-scale preparations need to be made, which
makes this procedure labour intensive. 
Despite several improvements in production as well as in
concentration of rAAV vectors, this hurdle still remains (Gao et al,
1998; Grimm et al, 1998; Clark et al, 1999). These difficulties
prompted us to explore an alternative production method consis-
ting of 2 steps. The first step is a classical co-transfection which is
followed by an amplification round of rAAV particles in the pres-
ence of wtAAV and adenovirus particles on HeLa cells. The
presence of wtAAV, in the final rAAV stock was considered as
potentially beneficial in light of its tumour suppressive properties.
We explored the potential of this preparation of recombinant adeno-
associated viral vectors and wtAAV to transduce human epithelial
ovarian cancer cells. Transduction efficiency by this rAAV viral
system was compared to a recombinant adenovirus vector. 
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MATERIALS AND METHODS 
Cell lines 
HeLa, HEK-293 and the epithelial ovarian cancer cell lines:
SKOV3, NIH-OVCAR3 and MDAH 2774 were purchased from
the ATCC (Manassas, VA, USA). 
Cells were maintained in their recommended media (HeLa and
HEK-293 cells: Dulbelcco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal calf’s serum (FCS), 50 IU ml–1 peni-
cillin (P) and 50 µ g ml–1 streptomycin (S), SKOV3: McCoy’s 10%
FCS P/S, NIH-OVCAR3: RPMI 20% FCS P/S, MDAH 2774:
Leibovitz 10% FCS P/S. 
293pTP cells were a gift from Dr J Schaack, University of
Colorado, Denver, USA. Cells were maintained in DMEM 10%
FCS P/S and hygromycin 25 µ g ml–1 (Schaack et al, 1996;
Maxwell et al, 1998). 
Media and supplements were supplied by GIBCO, Life
Technologies, Gaithersburg, MD, USA. 
Cells were grown in a humidified chamber with 5% CO2 at
37˚C. 
Production of viruses 
1. rAAV-GFP particles were generated by co-transfection of
HEK-293 cells (5 × 106 cells/10-cm plate) with the pTR-UF2
plasmid which contains the humanized form of green fluores-
cent protein (GFP) (Zolothukin et al, 1996) and the pIM45
plasmid which contains the AAV rep and cap sequences (map
positions: 190–4489). Lipofectamine was used according to
the suppliers instructions (GIBCO). 6 hours after transfection,
cells were infected with wild-type adenovirus (MOI 1) for 2
hours. (pTR-UF2 and pIM45 were gifts from N Muzyczka and
SL Zolothukin, University of Florida and L Tenenbaum,
Université Libre de Bruxelles.) 
After 72 h a lysate was collected and treated by 3 cycles of
freeze/thawing, followed by heat inactivation of adenovirus
(30 min, at 56˚C). This crude lysate was centrifuged (Beckmann)
at 8000 rpm for 15 min at 4˚C. Afterwards the supernatant was
passed through a 0.20 µ m filter (Sartorius, Goettingen,
Germany), aliquoted in 2 ml fractions and stored at –80˚C. 
2. rAAV-GFP particles were then amplified by co-infecting HeLa
cells (5 × 106 cells/10 cm plate) with equal amounts of rAAV-
GFP and wtAAV infectious particles (103/103) followed by
adenovirus infection at a MOI of 1. After 3 days the lysate was
collected and treated as described above. These rAAV-GFP
particles (amplified stock) were subsequently concentrated,
purified by column affinity chromatography using Cellufine
sulfate media (Amicon Division, WR Grace & Co, Danvers,
MA, USA) according to Tamayose et al (1996). A 35 ×
115 mm column was used. Sample (amplified rAAV-GFP
crude lysate, titre around 106 IP ml–1) was loaded on the
column, followed by washing with PBS, until absorbance
readings at 280 nm were below 0.01 (GeneQuant, Pharmacia,
Cambridge, England). The particles were eluted by 1.0 M
NaCl solution. Individual fractions (3.5 ml) were tested for the
presence of infectious particles (by in situ replication centre
assay). The final numbers of particles in separate preparations
were in the range of 107–108. The particles were stored at
–80˚C after dialysis (Slide-A-Lyzer, Pierce, Rockford, II,
USA) against PBS for use in transduction experiments. No
rAAV-GFP particles could be detected in the run through frac-
tions during sample loading. Recovery was around 50%. The
ratio wtAAV/rAAV was unaffected by chromatography. 
3. Wild-type AAV 2 was generated by transfection of HEK-293
cells with pSM620 (containing the entire wild type AAV
genome, a kind gift from P Hermonat, University of Arkansas,
Little Rock, USA) and lipofectamine, followed by adenovirus
infection at a MOI of 5. 
The crude lysate was harvested after 3 days and treated as
described above. 
4. Adenovirus serotype 2 (wt Ad) was propagated in HEK-293
cells, the lysate was collected after full cytopathic effect,
freeze/thawed 3 times and purified by caesium chloride
gradient ultracentrifugation. An opalescent band at 1.33 g ml–1
was recovered and dialysed against PBS. The concentrate was
diluted 1:2 in TRIS-HCl pH 8.0-Glycerol 50%. 
5. Ad5del308∆ pTP (again a gift from Dr J Schaack) was ampli-
fied in complementing 293pTP cells at a MOI > 10. After 3
days the lysate was collected, freeze/thawed 3 times and
centrifuged at 8000 rpm at 4˚C for 15 minutes. A titre of
106IP ml–1 lysate was obtained. 
6. Recombinant adenoviral particles, rAd-GFP were generated,
purified and titrated according to the protocol described by
T-C He et al (1998) and available at www.coloncancer.org.
The necessary plasmids were obtained with permission of B
Vogelstein (John Hopkins, Baltimore). The final preparation
was stored at –20˚C. Titres were determined by transduction
on HEK-293 cells after 18 hours (1–2 × 108 efu ml–1). Based
on these titres MOIs for rAd-GFP were determined. No wild-
type adenovirus could be detected in the stock neither by PCR
(for Ela region) nor by transfer experiments. 
Titration of rAAV (crude lysate) stocks 
Three methods were used: 
1. Dot blot hybridization assay. A dot blot assay was performed
as described in Basic Methods in Molecular Biology (Davis
et al, 1986, p 147–149). All DNA samples were applied on
nitrocellulose membranes (Hybond; Amersham,
Buckinghamshire, England) by a Biorad blotting apparatus
(Hercules, CA, USA). The membranes were hybridized with
P32 labelled PCR-based specific probes. Titres were estimated
through comparison of the sample signals with standard
plasmid DNA dilutions (Phospho-imager, Biorad). 
2. Transduction assay. 5 × 105 HeLa cells well–1 were plated in a
6-well plate. The next day the cells were infected with rAAV-
GFP particle stock (co-transfection or amplified) and wtAAV
plus Ad virus were added, in DMEM 2% FCS. After 2 h the
supernatant was removed and DMEM 10% FCS was added.
48 h after infection the number of green cells was counted
using an AXIOVERT 25 fluorescence microscope (Zeiss,
Oberkochen, Germany). 
3. In situ replication centre assay (RCA). Briefly, 5 × 105 HeLa
cells well–1 were seeded. The next day cells were infected with
serial dilutions of rAAV-GFP particle stock and wtAd in
DMEM 2% for 2 hours. WtAAV was added only when rAAV-
GFP particles were titrated. 24 h after infection the cells were
treated as described by L Tenenbaum et al (1999). Briefly,
after removal of the medium, cells were washed twice.
Nitrocellulose membranes were then firmly pushed on thecells and wetted with buffer (Tris 1M pH 8), which lyses the
cells, followed by denaturation with NaOH 0.5 M NaCl 
(3 × 1 min), neutralization with NaCl 1.5 M Tris 0.5 M–1
pH 8 (3 × 1 min) and washing with SSC 2 × (3 × 1 min). After
baking the membranes for 2 h at 80˚C, they were hybridized
overnight with P32-labelled probes. The probes were PCR-based
and recognize a 362 bp sequence of GFP (bases 136–498) or a
516 bp rep sequence (bp 753–1269). Replication centres were
counted after autoradiography and the viral infectious particle
(IP) titres were calculated taking into account the dilution
factors. Whenever the number of individual centres could not
be estimated due to high density, phospho-imaging was used
for quantification. 
Infection of ovarian cancer cell lines 
Infection with rAAV-GFP 
NIH-OVCAR3, SKOV3, MDAH 2774 and one control cell line
(HeLa) (1 × 104 cells well–1, in triplicate) were infected with puri-
fied rAAV-GFP particles at MOI 1, 10 and 100 (IP cell–1). PBS
without particles (mock-infected), wtAAV infection at MOI 10 IP
cell–1 and untreated cells served as controls. After 18–24 h the
supernatant was removed and replaced by fresh medium. In a
second set of conditions rAAV-GFP particles were administered
repeatedly (MOI 1 IP cell–1, once daily for 5 days) without replace-
ment of the supernatant and compared to single administration of
rAAV-GFP at MOI 1 (without replacement of supernatant). Controls
included mock (PBS) and wt AAV infections in similar conditions.
Transduction was evaluated daily using an Axiovert 25 fluores-
cence microscope (Zeiss) for 10 days. 
Another set of experiments consisted of co-infecting these cell
lines with rAAV-GFP and adenovirus (wtAd or Ad5del308∆ pTP)
for 2 hours in serum-free medium which was then replaced by
serum-containing medium. GFP expression was evaluated daily
for 4–6 days. 
Cell counts were performed using an ocular with a counting
frame (area 100 squares). Total cell numbers were calculated
based on at least 3 different counts of minimal 10 squares well–1. 
Infection with rAd-GFP 
The same set of epithelial ovarian cancer cell lines was used to
evaluate transduction efficiency by rAd-GFP vectors. Again infec-
tion at increasing MOIs (1–10 –100 expression forming units cell:
(efu)/cell) was tested. GFP expression was analysed as described
above. Controls included uninfected cells and particle storage
buffer alone in a volume equal to the infected cells. 
Immunocytochemistry 
After fixation in formaldehyde 4% cells were subsequently
exposed to: (1) H2O2 0.1% in methanol 10 min; (2) normal goat
serum + BSA for 20 min; (3) polyclonal rabbit anti-GFP (Santa-
Cruz, Santa-Cruz, Ca, USA) dilution of 1/400 at 4˚C overnight;
(4) goat anti-rabbit biotin 1/300 (Amersham-Pharmacia,
Roosendaal, Nl), 30 min at room temperature; (5)
streptABComplex/HRP (DAKO, Glostrup, Denmark), 30 min at
room temperature; and (6) diaminobenzidine (DAB) 5 min at
room temperature (Sigma-Aldrich, Bornem, Belgium). A more
intense staining was obtained by CuSO4 followed by counter-
staining with haematoxylin. Slides were dehydrated and mounted.
Sections were evaluated and photographed under an Olympus BX
41 microscope using a DP-11 digital camera (Olympus, Hamburg,
Germany). 
RESULTS 
Generation of recombinant AAV-GFP vectors by wt AAV
assisted amplification on HeLa cells 
A 2-step strategy for generation of high-titre rAAV preparations
was developed. Plasmid co-transfection of HEK-293 cells for
generation of rAAV particles on a small scale was followed by
amplification of these rAAV particles on HeLa cells with wtAAV
as a complementor virus and adenovirus as a helper virus. On
average non-purified rAAV stocks made by co-transfection
contained 104 infectious recombinant adeno-associated virus parti-
cles ml–1 and were free of detectable wtAAV. These titres are too
low for use in in vitro and in vivo experiments in which a MOI > 1
is to be used. Amplification of rAAV-GFP particles in the presence
of wtAAV and adenovirus was investigated on 2 cell lines (HeLa
and HEK-293), in an attempt to increase the yield of recombinant
AAV-GFP particles. Yields of infectious rAAV-GFP particles on
HeLa cells were higher when compared to HEK-293 cells. The
highest amplification factor on HeLa cells was obtained when rAAV-
and wtAAV-infectious particles were added in equal amounts. 
This approach led consistently to an amplification of rAAV
particles on HeLa cells by 103–104 fold, when compared to the
initial amount of infectious rAAV particles. Amplification on
HEK-293 cells was 5–10-fold lower. 
The rAAV (amplified) stocks generated with this method were
further characterized. The titres of rAAV particles as well as wt
AAV particles were estimated by dot blot (genomic particles),
transduction (rAAV)- and in situ replication centre assay (Table 1).
Titres derived from in situ replication centre assay (infectious
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Table 1 Characterisation of crude lysate of amplified rAAV-GFP stocks 
Particles ml–1
Titration method rAAV-GFP Ad 2 wtAAV 
Dot blot assay 3.2 109 +/– 2.2 109 N.D 1.4 1010 +/– 1.8 109
Transduction assay 3.6 107 +/– 2.8 107 ––  
In situ replication assay 9.5 105 +/– 6.1 105 0 2.7 107 +/– 1.4 107
rAAV-GFP preparations obtained by amplification in HeLa cells, were characterised for their biological
activity (transducing units and infectious particle number) and their physical contents (genomic particle
number by dot blot assay) before concentration by column chromatography. The amount of rAAV-GFP,
wtAAV and Ad 2 particles was determined. Data presented are the average (+/– SD) of results obtained
with at least three separately prepared rAAV-GFP stocks. N.D = not determined. particles ml–1) were used to calculate the volume needed to infect
cells at different MOIs in subsequent experiments. Column chro-
matography (Tamayose et al, 1996) was performed to concentrate
and purify the stocks. 
The ratio between infectious and genomic rAAV particles was
estimated to be 1 to 100–1000 in these preparations. The ratio
between rAAV-GFP and wtAAV particles was 1/10–100. 
After adenovirus heat inactivation and column purification, no
replicative adenoviral particles could be detected in the rAAV-GFP
stocks by in situ replication centre assay hybridizing with an aden-
oviral probe. 
Transduction efficiency of human epithelial ovarian
cancer cell lines with rAAV vectors in vitro 
3 ovarian cancer cell lines: NIH-OVCAR3, SKOV3, MDAH 2774
and HeLa cells were infected with purified rAAV-GFP particles
from an amplified stock to study the transduction efficacy of rAAV
vectors on epithelial ovarian cancer cells. A number of experi-
mental conditions were studied. Single administration at
increasing MOIs of 1, 10 and 100 was examined on these 4 cell
lines. Repeated administration was evaluated on NIH-OVCAR3
and MDAH 2774 cells, at a MOI of 1 for a 5-day period. Also,
continued exposure of the cells to rAAV-GFP particles was studied
on these 2 cell lines. 
Under all of these circumstances transduction efficiencies were
extremely low (< 5%) (Table 2). Neither did they improve with
increasing MOIs (10–100). There was only a minor improvement
(from < 1% to 3%) in transduction efficiency when NIH-
OVCAR3 cells were continuously exposed to rAAV-GFP particles
at a MOI of 1. The effect of which was equal to repeated adminis-
tration at the same MOI. 
GFP transduction of MDAH 2774 cells, transferred to a larger
dish on day 4 after infection suddenly increased on day 6 yielding
maximum transduction percentages of 2.8% (MOI 1), 1.3% (MOI
10) and 2.3% (MOI 100) on day 7. However simultaneously,
rAAV-GFP-infected MDAH 2774 cells also started to round up
and detach, whereas all controls continued to grow. The super-
natant of all cell lines taken at day 8 was analysed for the presence
of adenovirus. In situ replication centre assay after hybridizing
with an adenoviral probe revealed unexpectedly the presence of
adenovirus in the supernatant of the MDAH 2774 cell line, while
no signal could be detected in the supernatant of the other cell lines
(results not shown). This suggests presence of a small, undetected
amount of wild-type adenovirus in the rAAV-GFP stock used and
which under these experimental conditions is able to proliferate in
MDAH 2774 cells to a detectable level. 
Consistent with previous reports, HeLa cells also proved diffi-
cult to transduce with purified rAAV-GFP particles, resulting in
very low to absent GFP expression (Qing et al, 1997, 1998;
Tenenbaum et al, 1999). 
MDAH 2774, SKOV3 and HeLa cells were not much influ-
enced in their growth by the infection with rAAV-GFP or wtAAV.
All conditions (including controls) reached confluence between
days 3–4. 
In contrast, in the NIH-OVCAR3 cell line a cytopathic effect
was observed after infection with the rAAV-GFP particles as well
as with wtAAV (MOI 10) infection alone, leading to 100% cell
death by day 7 in rAAV-GFP-infected cells (condensed nuclei and
detached cells). Only 30% of the wtAAV-infected cells survived,
whereas mock-infected and untreated cells continued to grow and
reached confluence by the end of the observation period. This
effect on the cell number seemed to be independent of the MOIs
(1–5–10–50) used for both rAAV/wtAAV infection as well as
wtAAV infection (data not shown). 
Effect of adenovirus on the transduction efficiency of
ovarian cancer cells 
The low transduction efficiency of ovarian cancer cells could be
due to either problems of recombinant viral particle entry or ineffi-
cient intracellular processing and expression of the vector. To
elucidate this, wild-type adenovirus (MOI 0.1) was added to the 3
ovarian cancer cell lines together with rAAV-GFP particles at a
low MOI (0.1). 
Under these conditions GFP expression was clearly observed
within 24 hours in the cell lines by fluorescence microscopy and
by immunocytochemistry, used as an additional means to demon-
strate transduction (Figure 1, right panel). It has been reported
(Brewis et al, 2000) in other settings that this method is more
sensitive than direct fluorescent microscopy for GFP detection. 
Only very few cells were stained in absence of adenovirus after
72 h (Figure 1, left panel), when exposed to rAAV-GFP at an MOI of
1. The finding of GFP-positive cells in the presence of adenovirus
Transducing ovarian cancer cells with rAAV or rAd vectors 1595
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Table 2 Maximal transduction efficiency (%) of rAAV-GFP particles on ovarian cancer cell lines 
rAAV-GFP IP/cell
Cell lines MOI 1 MOI 10 MOI 100 MOI 1/daily ×  5 MOI 1 continued exposure 
SKOV3 – <1 <1 <1 N.D N.D 
MDAH 2774 – <1 <1 <1 <1 <1 
+ 2.1 +/– 1.5 N.D N.D N.D N.D 
HeLa – <1 <1 <1 N.D N.D 
+ 7.4 +/– 1.0 N.D N.D N.D N.D 
NIH-OVCAR3 – <1 <1 <1 3.3 +/– 1.3 3.3 +/– 0.9 
+ 13.0 +/– 1.8 13.6 +/– 4.6 17.2 +/– 3.3 N.D N.D 
Maximum transduction efficiency (%) in time, after infection of, SKOV3, MDAH 2774, HeLa and NIH-OVCAR3 cells with rAAV-GFP particles 
at increasing MOI’s (1, 10, 100 transient exposure) or with repeated administration at a MOI of 1 for 5 days or continuous exposure at MOI 1.
The effect on transduction with (+) and without (–) co-infection at MOI 1, with wild type or a mutant (replication defective) adenovirus
(Ad5del308∆ pTP) is shown. Transduction efficiency was calculated as the percentage of GFP positive cells over the total cell number. 
Observation period: ten days. Green fluorescent cells were present on day three (without adenovirus) and within 24 hours with adenovirus.
Data presented are as the mean +/– SD of three experiments. MOI’s are defined in infectious particles/cell, based on titers determined by in
situ replication center assay. N.D: not done. 1596 J Vermeij et al 
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coincided with the finding of replication centres after in situ
hybridization of the cell lines with a GFP probe (Figure 2). In the
absence of adenovirus, these centres were not found and green
fluorescent cells were absent. This is an indication that replicative
(double-stranded) forms of rAAV-GFP DNA are needed for
expression and adenovirus helps to generate these forms in the cell
lines examined. A similar observation has already been made by
others for different cell types (Ferrari et al, 1996; Fisher et al,
1996; Peng et al, 2000). Help from wild-type adenovirus can only
be observed for a limited time, due to its replication which causes
a cytolytic effect within 72 hours after infection. Therefore a
mutant, replication-defective adenovirus (Ad5del308∆ pTP, E1 and
E4ORF6 expressed) was also evaluated. Since this adenovirus
mutant does not replicate, cell death was far less dramatic when
compared to wild-type adenovirus co-infection and observations
could be extended over longer periods (5–6 days). 
To further assess the transduction efficiencies in the presence of
adenovirus MDAH 2774, HeLa and NIH-OVCAR3 cells were
co-infected with rAAV-GFP (MOI 1) and Ad5del308∆ pTP or wt
adenovirus (MOI 1). A slight increase in expression of GFP in
MDAH 2774 (2.1%) and HeLa (7.4%) could be observed but a
more significant increase was only found in NIH-OVCAR3 cells
Figure 1 Immunocytochemistry for GFP on MDAH 2774 (A,B), NIH-OVCAR3 (C,D) and HeLa (E,F) cells. Cells were infected with rAAV-GFP at 
a MOI of 1 (I.P/cell) in the absence of wild-type adenovirus (A,C,E) and at a MOI of 0.1 (I.P/cell) in the presence of wild type adenovirus (B,D,F). Cells were
fixed after 24 h (B,D,F) and 72 h (A,C,E). Magnification 200 × , counterstaining with haematoxylin 
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(13%) (Table 2). Therefore, in addition, the effect of increasing
the MOIs of rAAV-GFP (MOI 10–100) was studied on these
cells (Table 2, NIH-OVCAR3 + Ad5del308∆ pTP). Transduction
efficiencies in a range similar to rAAV-GFP MOI 1 were found,
indicating a limitation in transduction again independent of rAAV-
GFP concentration. 
Transduction efficiency of epithelial ovarian cancer cell
lines with rAd-GFP in vitro 
The transduction efficiencies observed with the recombinant
adeno-associated virus system in ovarian cancer cells, even in the
presence of appropriate help, such as wt or mutant adenovirus or
genistein (data not shown) are too low for gene transfer when ther-
apeutic genes are to replace GFP. In corrective gene therapy for
example a near 100% transduction efficiency would be needed.
We therefore compared the rAAV-GFP system to the recombinant
adenoviral vector system which has already been used in clinical
protocols and evaluated the transduction efficiency of this vector
on the same epithelial ovarian cancer cell lines (Table 3). 
In general, transduction efficiencies with rAd-GFP were much
higher in all cell lines examined, reaching more then 50% within
48 hours when a MOI of 10 was used. There was a clear
dose–response effect. 
Cytotoxic effects were observed in all cell lines. MOIs of 100 or
more caused a lethal effect in the 4 cell lines within 18 hours. This
effect is not vector- or GFP-related, since GFP expression was
absent at this time and a similar effect could be observed when
equal volumes of just particle storage buffer (glycerol-containing)
were put on the cells. 
At a MOI of 10 a growth inhibitory effect was noticed after 48
hours of infection in all cell lines. By then the cells were already
strongly expressing GFP. This was not observed in control condi-
tions in which the cells only received storage buffer. To exclude
the presence of wild-type adenovirus, PCRs for the E1a region
were performed on the supernatants of the cells as well as transfer
experiments. From these tests there was no evidence that wtAd
virus was responsible for these effects. Most likely the inhibition is
due to the rAd vector itself or to the GFP (Lui et al, 1999). 
DISCUSSION 
Over the past few years recombinant adeno-associated viruses
have gained interest as vectors for gene transfer in human gene
therapy (Hallek and Wedntner, 1996). Production methods for
recombinant adeno-associated virus have improved (Grimm et al,
1998) but there is still no uniform production method and most
procedures are laborious because they need to be performed on a
large scale to obtain enough viral particles for in vivo experiments. 
In this paper we report our exploration of an alternative
approach for the production of rAAV particles, for use in cancer
gene therapy. The strategy involves a 2-step procedure in which
rAAV particles generated by co-transfection (on a small scale) are
subsequently amplified on HeLa cells in the presence of wild-type
AAV virus and adenovirus, followed by concentration using
column chromatography. Our results demonstrate that this proce-
dure is a less laborious alternative with a high amplification factor
(103–104) for production of rAAV stocks when compared to large-
scale co-transfection methods. 
The final stocks obtained by our method contain an excess of
wild-type AAV particles. For corrective cancer gene therapy this
would not necessarily be a disadvantage since tumour-suppressive
properties have been attributed to wild-type adeno-associated
virus (Schlehofer, 1994). In addition there have been reports
demonstrating an inhibiting effect of the AAV rep gene on cellular
transformation (Khleif et al, 1991; Kube et al, 1997; Batchu et al,
1999). Wild-type AAV infection has also been found to increase
the sensitivity of malignant cells to chemotherapy and radio-
therapy; this could be an advantage when treatment modalities are
combined (Walz et al, 1992; Hillgenberg et al, 1999). There is
however a necessity to use wtAAV as a control in experimental
settings in order to be able to identify the specific effect of the
therapeutic insert within the rAAV vector. 
There are only limited data on the efficiency of rAAV vectors for
gene transfer into human cancer cells (Hoerer et al, 1997; Maass et al,
1998; Veldwijk et al, 1999). We studied the transduction efficiency
of rAAV-GFP vectors on 3 ovarian cancer cell lines in vitro. 
The basic transduction efficiency with rAAV-GFP/wtAAV in all
ovarian cancer cell lines in our study was very low. The transduc-
tion efficiency on these cells could however be improved in
various ways: to a minor extent with continuous exposure of the
cells to rAAV-GFP or by repeated administration as studied on
NIH-OVCAR3 cell line. With the help from adenovirus (wild-type
or mutant) a larger improvement in transduction efficiencies was
observed, as reported by others (Ferrarri et al, 1996; Fisher et al,
Table 3 Maximal transduction efficiency (%) of rAd-GFP particles on
ovarian cancer cell lines 
rAd-GFP (efu cell–1)
Cell lines MOI 1 MOI 10 MOI 100 
NIH-OVCAR3 34.0 +/– 8.2 50.8 +/– 6.3 toxic 
SKOV3 2.9 +/– 1.8 60.0 +/– 13 toxic 
MDAH 2774 8.3 +/– 1.7 71.1 +/– 1.8 toxic 
HeLa 21.6 +/– 7.5 51.1 +/– 9.4 toxic 
Maximum transduction efficiency (%) in time after infection of NIH-OVCAR3,
SKOV3, MDAH 2774 and HeLa cells with rAd-GFP particles, at increasing
MOI’s (1, 10, 100 continuous exposure). Transduction efficiency was
calculated as the percentage of GFP positive cells over the total cell number
(three representative areas/well). Experiments were done in triplicate. 
Observation period: five days. Green fluorescent cells were present 18 hours
after infection. Data presented are as the mean +/– SD. 
MOI’s are defined in expression forming units/cell, based on titers
determined with the transduction assay on HEK-293 cells (see Methods). 
Figure 2 NIH-OVCAR 3, SKOV 3 and MDAH 2774 ovarian cancer cells
coinfected with rAAV-GFP (MOI < 1 I.P) and (wild-type) adenovirus. Viral
particles were removed after 2 hours and cells were given fresh medium.
The in situ replication centre assay was started 28 hours after infection.
Membranes were hybridized with a P32-labelled GFP probe. Autoradiography
was developed after 4 hours. Without adenovirus present no signal could be
detected, even after long expositions (48 hours, data not shown). The
presence of replication centres coincided with detection of green fluorescent
cells. 
(1) NIH-OVCAR 3 (2) MDAH 2774 (3) SKOV 3 
12 31996; Qing et al, 1997, 1998; Mah et al, 1998). On NIH-OVCAR3
cells this increase also proved to be independent of the rAAV-GFP
concentration. Data published on transduction of hepato-cellular
carcinoma with rAAV are comparable to our findings (Peng et al,
2000). These authors also observed very low transduction efficien-
cies when infecting several HCC cell lines with rAAV containing a
reporter gene at increasing MOIs. The transduction efficiency could
be increased with the help of adenovirus as well as γ -radiation and
chemotherapy. 
The absence of an important dose–dependent effect and the effi-
cient transduction at low MOI in the presence of wild-type or
mutant adenovirus indicate that post-entry events rather than viral
uptake limit transduction efficiency of rAAV-GFP in these ovarian
cell lines. 
A possible explanation for the low transduction efficiencies
observed could be suppression of translation of rAAV vectors due
to the presence of the rep 78 protein from the wtAAV in the prepa-
ration (Takeuchi et al, 2000). This however seems less likely. We
performed small-scale in vitro experiments with rAAV particles
generated by co-transfection (these stocks are wtAAV-free) and
the same low transduction efficiency was obtained (data not
shown). 
Moreover the experiments by Peng et al on hepatocellular carci-
noma (HCC) were also performed with rAAV particles free from
wtAAV. 
The higher transduction efficiencies observed in ovarian carci-
noma cells tested by Maass et al could be due to various experi-
mental variables: cell types tested; freshly isolated tumour cells
versus cell lines; use of luciferase vs GFP as a reporter gene,
which have different detection methods (cell extracts vs life cells).
In addition in all experiments reported by Maass, the cells were
exposed to X-ray irradiation causing an increase in transduction
comparable to that obtained with an adenovirus super-infection at
a MOI of 10, while we only used a MOI of 1. 
The major hurdle for transduction by rAAV vectors, after entry
of the single-stranded DNA rAAV particles is the conversion to a
transcription-competent double-stranded DNA (Samulski et al,
1989; Fisher et al, 1996; Peng et al, 2000). Several cellular factors
play a role in this conversion. Recent publications could demon-
strate a correlation between the transduction efficiency by rAAV
vectors and the phosphorylation status of a cellular tyrosine
phospho-protein (ssD-BP) (Ferrari et al, 1996; Qing et al, 1997,
1998; Mah et al, 1998). This protein binds to the 3′ end of the AAV
genome. Transduction by AAV is related to the ratio between the
dephosphorylated and phosphorylated form of this protein.
Different cell types and tissues seem to have different ratios. No
specific data on the ratio between dephosphorylated and phophory-
lated ssD-BP in ovarian cancer cells or human tumours are currently
available. Our data are compatible with a role for the phosphory-
lated status of ssD-BP in the ovarian cancer cell lines used in
this study. Wild-type adenovirus and mutant adenovirus
(Ad5del308∆ pTP), which are known to increase the dephosphory-
lated/phosphorylated ratio of ssD-BP, mainly through the E4ORF6
protein, led to a higher GFP expression in these ovarian cancer
cells. At least a 5-fold increase in NIH-OVCAR3 transduction
compared to rAAV-GFP infection alone could be observed. 
The cytotoxicity observed in NIH-OVCAR3 and MDAH 2774
cells but not in SKOV3 and HeLa after exposure to rAAV-GFP/
wtAAV preparations should be discussed. 
Whereas SKOV3 and HeLa cells were unaffected in their growth,
a lethal toxicity was observed in NIH-OVCAR3. In NIH-OVCAR3
cells growth arrest and subsequent cell death eventually took place
in all conditions of viral infection (after the time points on which
GFP transduction was measured), suggesting an effect of wtAAV
since replicating adenovirus could not be detected in the super-
natants of infected cells. 
This cytopathic effect on NIH-OVCAR3 cells was independent
of either the MOIs of rAAV/wtAAV or wtAAV preparations used
and resembles the influence of wtAAV-2 infection on carcinoma
cells described by Bantel-Schaal (1990) regarding cell number and
morphologic alteration of these cells. 
It appears that NIH-OVCAR3 cells are so sensitive to these
toxic effects that even at the lowest MOI a maximal toxic effect
can be observed which explains the absence of a dose–response
effect. 
Kube et al (1997) reported a growth arrest on primary human
fibroblasts related to the presence of rep proteins associated and
encapsidated in mature rAAV particles. This effect was MOI-
dependent, however differences in susceptibility to AAV among
tumour cell types have been described and are most likely due to
different molecular pathways by which cells have become
immortal (Kube et al, 1997). 
The AAV-associated cytopathic effect was only observed on the
NIH-OVCAR3 cell line and not on MDAH-2774 and SKOV3,
although transduction efficiency of these cell lines was also low.
Therefore the poor transduction efficiency observed in all 3 ovarian
cancer cell lines could not be explained by the AAV-associated
toxicity. 
The late-onset cell death observed in the MDAH 2774 cells is
probably due to a lytic effect of contaminating adenovirus. The
presence of replicating wild-type adenovirus in the supernatant of
infected cells can explain the final sudden increase in transduction
observed in MDAH 2774 cells just before cell death occurred. The
presence of adenovirus is probably due to a small number of aden-
oviral particles (initially below the detection limit of the in situ
replication centre assay) in the original rAAV-GFP stock and to
unknown factors specific for the MDAH 2774 cell line which
favour adenovirus replication. 
Because of the low transduction efficiencies obtained with
rAAV, we wanted to compare this system to rAd transduction on
the same ovarian cancer cells. The rAd vectors are easier to
produce in large quantities and have already been used in clinical
protocols, including ovarian cancer. Infection of ovarian cancer
cells with rAd-GFP led to much higher transduction efficiencies
that were dose-dependent and independent of additional help.
Some cytopathic effects observed at lower MOIs could be
explained by toxic effects of the adenoviral proteins or even of the
recombinant GFP protein (Liu et al, 1999). 
In conclusion, based on the features of rAAV vectors we wanted
to explore their potential as vectors in corrective gene therapy for
epithelial ovarian cancer. However the production of large
amounts of rAAV particles has remained cumbersome. We tried to
overcome this hurdle by using the method proposed in this article.
This procedure proved to be an efficient and labour friendly way to
generate rAAV particles. We then used them to evaluate transduc-
tion efficiencies in epithelial ovarian cancer cells. We found that
ovarian cancer cells can be infected with rAAV vectors but signi-
ficant expression of the transgene needs help from either adeno-
virus or other enhancers of transduction which constitutes an
important obstacle for their application in vivo. In comparison rAd
vectors, easier to generate, led to high transduction percentages in
ovarian cancer cells in this study. For corrective therapeutic gene
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therapy strategies in human cancer a high transduction efficiency
is critical. Therefore, adenoviral vectors currently remain the
vectors of choice for gene transfer into human epithelial ovarian
cancer cells. 
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